Social Determinants of Health Predict Sleep–Wake Disturbances Among Patients Living With Primary Brain Tumors: A Cross-Sectional Analysis

IF 2.9 2区医学 Q2 ONCOLOGY

Cancer Medicine Pub Date : 2025-02-15 DOI:10.1002/cam4.70693

Michelle L. Wright, Hope Miller, Elizabeth Vera, Alvina A. Acquaye-Mallory, Brayden Chavis, Anna Choi, Ewa Grajkowska, Tricia Kunst, Morgan Johnson, Zuena Karim, Bennett McIver, Madhura Managoli, Jennifer Reyes, Terri S. Armstrong, Amanda L. King

{"title":"Social Determinants of Health Predict Sleep–Wake Disturbances Among Patients Living With Primary Brain Tumors: A Cross-Sectional Analysis","authors":"Michelle L. Wright, Hope Miller, Elizabeth Vera, Alvina A. Acquaye-Mallory, Brayden Chavis, Anna Choi, Ewa Grajkowska, Tricia Kunst, Morgan Johnson, Zuena Karim, Bennett McIver, Madhura Managoli, Jennifer Reyes, Terri S. Armstrong, Amanda L. King","doi":"10.1002/cam4.70693","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Introduction</h3>\n \n <p>Sleep disturbance (SD) and sleep-related impairment (SRI) significantly impact the lives of primary brain tumor (PBT) patients. We aimed to describe the prevalence of SD and SRI in this population, determine the reliability of the PROMIS-SD and PROMIS-SRI instruments, and identify predictive factors to support the development of targeted interventions for at-risk individuals.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>This cross-sectional study evaluated SD and SRI in PBT patients enrolled in a Natural History Study who completed 1-year follow-up questionnaires (<i>N</i> = 229). Demographic, clinical, and socioeconomic data were analyzed to identify factors associated with SD and SRI. Descriptive statistics were used to report the prevalence of sleep problems, and linear regression analysis was conducted to identify predictive factors. The reliability of sleep-related instruments was calculated using Cronbach's alpha.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>Fifteen percent of PBT participants reported clinically significant SD and 20% reported clinically significant SRI, which were associated with financial toxicity (<i>p</i> < 0.001), being unemployed (<i>p ≤</i> 0.02), and taking psychotropic medication (<i>p ≤ 0.</i>002). Good internal consistency was demonstrated by the SD (0.923) and SRI (0.925) questionnaires in this population.</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>In this study, social factors such as financial toxicity and employment status were associated with SD and SRI. Psychotropic medications also impacted SD and SRI in PTB survivors, but less so than financial toxicity. Social factors and other medications may impact sleep more strongly in PBT survivors than their previous treatment courses.</p>\n </section>\n \n <section>\n \n <h3> Implications for Cancer Survivors</h3>\n \n <p>SD and SRI can be impacted by multiple factors, including those not related to PBT treatment, which should be considered by their providers.</p>\n </section>\n </div>","PeriodicalId":139,"journal":{"name":"Cancer Medicine","volume":"14 4","pages":""},"PeriodicalIF":2.9000,"publicationDate":"2025-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cam4.70693","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Medicine","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/cam4.70693","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction

Sleep disturbance (SD) and sleep-related impairment (SRI) significantly impact the lives of primary brain tumor (PBT) patients. We aimed to describe the prevalence of SD and SRI in this population, determine the reliability of the PROMIS-SD and PROMIS-SRI instruments, and identify predictive factors to support the development of targeted interventions for at-risk individuals.

Methods

This cross-sectional study evaluated SD and SRI in PBT patients enrolled in a Natural History Study who completed 1-year follow-up questionnaires (N = 229). Demographic, clinical, and socioeconomic data were analyzed to identify factors associated with SD and SRI. Descriptive statistics were used to report the prevalence of sleep problems, and linear regression analysis was conducted to identify predictive factors. The reliability of sleep-related instruments was calculated using Cronbach's alpha.

Results

Fifteen percent of PBT participants reported clinically significant SD and 20% reported clinically significant SRI, which were associated with financial toxicity (p < 0.001), being unemployed (p ≤ 0.02), and taking psychotropic medication (p ≤ 0.002). Good internal consistency was demonstrated by the SD (0.923) and SRI (0.925) questionnaires in this population.

Conclusions

In this study, social factors such as financial toxicity and employment status were associated with SD and SRI. Psychotropic medications also impacted SD and SRI in PTB survivors, but less so than financial toxicity. Social factors and other medications may impact sleep more strongly in PBT survivors than their previous treatment courses.

Implications for Cancer Survivors

SD and SRI can be impacted by multiple factors, including those not related to PBT treatment, which should be considered by their providers.

Abstract Image

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

Cancer Medicine ONCOLOGY-

CiteScore

5.50

自引率

2.50%

发文量

907

审稿时长

19 weeks

期刊介绍： Cancer Medicine is a peer-reviewed, open access, interdisciplinary journal providing rapid publication of research from global biomedical researchers across the cancer sciences. The journal will consider submissions from all oncologic specialties, including, but not limited to, the following areas: Clinical Cancer Research Translational research ∙ clinical trials ∙ chemotherapy ∙ radiation therapy ∙ surgical therapy ∙ clinical observations ∙ clinical guidelines ∙ genetic consultation ∙ ethical considerations Cancer Biology: Molecular biology ∙ cellular biology ∙ molecular genetics ∙ genomics ∙ immunology ∙ epigenetics ∙ metabolic studies ∙ proteomics ∙ cytopathology ∙ carcinogenesis ∙ drug discovery and delivery. Cancer Prevention: Behavioral science ∙ psychosocial studies ∙ screening ∙ nutrition ∙ epidemiology and prevention ∙ community outreach. Bioinformatics: Gene expressions profiles ∙ gene regulation networks ∙ genome bioinformatics ∙ pathwayanalysis ∙ prognostic biomarkers. Cancer Medicine publishes original research articles, systematic reviews, meta-analyses, and research methods papers, along with invited editorials and commentaries. Original research papers must report well-conducted research with conclusions supported by the data presented in the paper.